A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Univ of Colorado Cancer Center
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Massachusetts General Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University, Siteman Cancer Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State Univ
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health Science Univ
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Maloney Hospital
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt Ingram Cancer Center
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Eastern Virginia Medical School
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
During the Phase 1 and Phase 2 portions of the study, participant eligibility criteria are identical except for prior treatment for anaplastic thyroid cancer (ATC). During Phase 1, eligible participants may have received prior chemotherapy while during Phase 2, eligible participants must be chemotherapy naïve.
Inclusion Criteria:
- Histologically or cytologically diagnosed, advanced ATC
- Measurable lesion(s)
- Lesion(s) (primary or metastatic) with viable tumor tissue accessible for repeated biopsy
- Age equal to or older than 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
- Adequate organ and bone marrow function
- Agreement to use effective contraception while on treatment and for equal to or greater than 3 months after end of treatment
- Pregnant or breastfeeding
Exclusion Criteria:
- Medical history of diabetes mellitus requiring treatment with insulin or oral agents; no pleural or pericardial effusion or clinically significant pulmonary or cardiovascular disease.
- Clinically active brain metastasis, uncontrolled seizure disorder, spinal cord compression, or carcinomatous meningitis
- Clinically significant active infection requiring antibiotic or antiretroviral therapy
- Concomitant use of other thiazolidinediones (TZDs)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Cohort 1; 0.15 mg CS-7017
Participants who received 0.15 mg twice daily (BID) oral CS-7017 and 135 [Dose Level 1a] or 175 [Dose Level 1b] mg/m^2 intravenous (IV) paclitaxel once every 3 weeks.
|
At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID.
At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
|
|
EXPERIMENTAL: Cohort 2; 0.30 mg CS-7017
Participants who received 0.30 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
|
At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID.
At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
|
|
EXPERIMENTAL: Cohort 3; 0.50 mg CS-7017
Participants who received 0.50 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
|
At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID.
At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Progression-free Survival in Participants After a Dosage of CS-7017 Administered Twice Daily in Combination With Paclitaxel Administered Once Every 3 Weeks to Participants With Advanced Anaplastic Thyroid Cancer (ATC)
Time Frame: From baseline up to disease progression or death, up to approximately 2 years postdose
|
Progression-free survival (PFS) was defined as the time from enrollment to the date of the first objective documentation of disease progression or death resulting from any cause, whichever comes first.
Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as at least a 20% increase in the sum of diameters of target lesions.
|
From baseline up to disease progression or death, up to approximately 2 years postdose
|
|
Overall Survival in Participants After a Dosage of CS-7017 Administered Twice Daily in Combination With Paclitaxel Administered Once Every 3 Weeks to Participants With Advanced Anaplastic Thyroid Cancer (ATC)
Time Frame: From baseline up to date of death, up to approximately 2 years postdose
|
Overall survival (OS) was defined as the time from the date enrollment to the date of death.
|
From baseline up to date of death, up to approximately 2 years postdose
|
|
Best Overall Response in Participants After a Dosage of CS-7017 Administered Twice Daily in Combination With Paclitaxel Administered Once Every 3 Weeks to Participants With Advanced Anaplastic Thyroid Cancer (ATC)
Time Frame: From baseline up to disease progression or the development of unacceptable toxicity, up to approximately 2 years postdose
|
The best overall response was the best response (in the order of confirmed complete response [CR], confirmed partial response [PR], stable disease [SD], and progressive disease [PD]) among all overall responses recorded from the start of treatment until the subject withdraws from the study.
If there is no tumor assessment after the date of enrollment, the best overall response is classified as Unknown.
|
From baseline up to disease progression or the development of unacceptable toxicity, up to approximately 2 years postdose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events, Summarized by Worst CTCAE Grade (≥3) and Preferred Term After Administration of CS-7017 Combined With Paclitaxel Administered to Participants With Advanced Anaplastic Thyroid Cancer (ATC)
Time Frame: From baseline up to 30 days after last dose, up to approximately 2 years
|
Treatment-emergent adverse events (TEAEs) are defined as adverse events that started or worsened after the first dose of any study drug (after Day 1 or first day of CS-7017 monotherapy) but adverse events occurring more than 30 days after the last dose are not considered TEAEs unless also considered to be related (possibly, probably, or definitely) to study drug.
|
From baseline up to 30 days after last dose, up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Director Clinical Development, Daiichi Sankyo, Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Thyroid Diseases
- Thyroid Neoplasms
- Thyroid Carcinoma, Anaplastic
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Efatutazone
Other Study ID Numbers
Other Study ID Numbers
- CS7017-A-U103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.